Cannabidiol for Quitting Smoking
What You Need to Know Before You Apply
What is the purpose of this trial?
Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any over-the-counter drugs, herbal supplements, vitamins, or prescription medications (except birth control) at least 14 days before the study sessions, as they might interfere with the study results or your safety.
Is cannabidiol (CBD) safe for human use?
How does the drug Cannabidiol (CBD) help people quit smoking?
Cannabidiol (CBD) is unique in helping people quit smoking by reducing withdrawal symptoms and anxiety, which are common challenges during nicotine abstinence. Unlike traditional nicotine replacement therapies, CBD works by modulating the endocannabinoid system, potentially reducing cravings and cigarette consumption.678910
What data supports the effectiveness of the drug Cannabidiol (CBD) for quitting smoking?
Who Is on the Research Team?
Dustin C Lee, PhD
Principal Investigator
Behavioral Pharmacology Research Unit, Johns Hopkins Medical Center
Are You a Good Fit for This Trial?
Adults aged 18-65 who smoke more than 10 cigarettes a day for over a year, want to quit in the next two months, and are generally healthy can join. They must be willing to try quitting as part of the study and use effective contraception if applicable. People with other substance use disorders, current serious health issues, or on certain medications cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive twice-daily oral CBD and matched placebo in a double-blind, within-subject, double-crossover design to evaluate short-term tobacco abstinence
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cannabidiol
Cannabidiol is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator